Impax reaches $20 million deal to end trial over generic drug’s delay
BOSTON (Reuters) – Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a…